Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD

Abstract

Triple therapy with fluticasone furoate, umeclidinium, and vilanterol resulted in a lower rate of moderate or severe COPD exacerbations than fluticasone furoate-vilanterol or umeclidinium-vilanterol in this population. Triple therapy also resulted in a lower rate of hospitalization due to COPD than umeclidinium-vilanterol. (Funded by GlaxoSmithKline; IMPACT ClinicalTrials.gov number, NCT02164513 .).

Keywords

Affiliated Institutions

• GlaxoSmithKline (India) IN
• Royal Devon and Exeter Hospital GB
• New York Hospital Queens US
• NewYork–Presbyterian Hospital US
• Temple University US
• Johns Hopkins Medicine US
• Gentofte Hospital DK
• Manchester University NHS Foundation Trust GB
• University of Alabama at Birmingham US
• University College London GB
• Manchester Academic Health Science Centre GB
• University of Michigan US
• GlaxoSmithKline (United Kingdom) GB
• Presbyterian Hospital US
• University of Pennsylvania US
• Cornell University US
• Johns Hopkins University US
• Research Triangle Park Foundation US
• University of Copenhagen DK
• GlaxoSmithKline (United States) US

Related Publications